Braveheart Bio

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies for cardiovascular diseases. Braveheart's small molecule candidate therapeutic BHB-1893 is a selective cardiac myosin inhibitor designed to improve cardiac function in HCM patients. In HCM, hypercontraction leads to myocardial thickening and a decline in the heart’s filling and pumping capacity. HCM is one of the most common rare diseases, affecting 1 in 500 people in the United States.